Jemincare Group of Nanchang has started a China Phase I clinical trial of an anti-SARS-CoV-2 neutralizing antibody. In preclinical studies, JMB2002 effectively neutralized live virus infection of Vero E6 cells and showed potent binding and blocking activity. The company said the candidate is derived from a naive human B cell antibody library of healthy donors, a stable cell line that ensures the product's consistency and stability. In 2018, Jemincare established a Research Institute in Shanghai Zhangjiang Science City.

JMB2002 is derived using the company's phage-to-yeast platform, which allows researchers to pinpoint candidates from over 10 billion antibody molecules in 19 days.

Jemincare  focuses on R&D of novel drugs with a pipeline aimed at diseases in cancer, central nervous system, respiratory system, cardiovascular and cerebrovascular systems. The company has recruited over 400 R&D scientists in five research centers for products that include biologics, novel small molecules, novel drug delivery methods, generic drugs and traditional Chinese medicines.

Disclosure: none.